JANX Q2 2025 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

JANXJanux Therapeutics, Inc.

$852M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$45M

Net Income

-$34M

EPS (Diluted)

$-0.55

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$42M

Stockholders' Equity

$991M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$9M	-100.0%
Gross Profit	$0	$8M	-100.0%
Operating Income	-$45M	-$14M	-226.4%
Net Income	-$34M	-$6M	-468.2%